CHIRON VIES FOR GENE THERAPY LEADERSHIP WITH $95 MIL. ACQUISITION OF VIAGENE; EXISTING COLLABORATIONS WITH GREEN CROSS AND BAYER EXPECTED TO CONTINUE
Executive Summary
Chiron will expand its gene therapy portfolio to non-cancer indications with the proposed acquisition of Viagene announced April 24.